NICE guidance - rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
NICE have suggested that (1):
- rituximab, in combination with glucocorticoids, is recommended as an option for inducing remission in adults with anti-neutrophil cytoplasmic antibody [ANCA]-associated vasculitis (severely active granulomatosis with polyangiitis [Wegener's] and microscopic polyangiitis), only if:
- further cyclophosphamide treatment would exceed the maximum cumulative cyclophosphamide dose or
- cyclophosphamide is contraindicated or not tolerated or
- the person has not completed their family and treatment with cyclophosphamide may materially affect their fertility or
- the disease has remained active or progressed despite a course of cyclophosphamide lasting 3-6 months or
- the person has had uroepithelial malignancy.
- further cyclophosphamide treatment would exceed the maximum cumulative cyclophosphamide dose or
Notes (1):
- rituximab is a genetically engineered chimeric (mouse/human) monoclonal antibody that depletes B cells by targeting cells bearing the CD20 surface marker
Reference:
- NICE. Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. Technology appraisal guidance TA308. Published: March 2014
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.